Comparison · NCT03615040-76a5b24d
Anti-ST2 vs Placebo: Adverse Event Rate in the 48 Weeks of the Trial From First Dose
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Anti-ST2 vs Placebo: Adverse Event Rate in the 48 Weeks of the Trial From First Dose. Trial comparisons, record NCT03615040-76a5b24d. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03615040-76a5b24d
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.81 | 0.667 | 0.9 | wilson | |
| Risk in group 2 | 0.718 | 0.562 | 0.835 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0916 | -0.0926 | 0.272 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.13 | 0.882 | 1.44 | log | |
| Odds ratio, group 1 over group 2 | 1.67 | 0.591 | 4.72 | log | |
| Number needed to treat, for one more participant with the outcome on Anti-ST2 than on Placebo | 10.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Anti-ST2 | Anti-ST2 (MSTT1041A) received as subcutaneous injection by infusion pump at 490mg every 4 weeks over a 48 week treatment period.~MSTT1041A: MSTT1041A (RO7187807; formerly made by Amgen \[AMG\] and referred to as AMG 282) is a novel biopharmaceutical that blocks signaling of interleukin (IL)-33, an inflammatory cytokine of the IL-1 family and member of the newly discovered alarmin class of molecules. IL-33 is released from airway epithelial cells in response to allergens, irritants, and infection. IL-33 release can trigger acute exacerbations in both asthma and COPD. MSTT1041A has the ability to block inflammation,prevent exacerbations, and improve lung function and quality of life.~Anti-ST2 is presented as sterile, clear, and colourless to slightly yellow liquid. Each sterile vial is filled with a 1 mL deliverable volume of 70 mg/mL. It is formulated with 15 mM sodium acetate, 9.0% (w/v) sucrose, 0.01% (w/v) polysorbate 20, pH 5.2. | 34 | 42 | OG000 |
| Group 2 | Placebo | Placebo (no active component) received as subcutaneous injection by infusion pump at 490mg every 4 weeks over a 48 week treatment period.~Placebo: Placebo for Anti-ST2 (MSTT1041A) is formulated with 10 mM sodium acetate, 9.0% (w/v) sucrose, 0.004% (w/v) polysorbate 20, pH 5.2, and is supplied in an identical vial configuration. | 28 | 39 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Adverse Event Rate in the 48 Weeks of the Trial From First Dose
- Description
- Number of Participants with Adverse Events in the 48 Weeks of the Trial From First Dose
- Time frame
- Weeks 0 , 4, 12, 24, 26, 48
- Population
- Safety population
Source ClinicalTrials.gov
Trial
- Title
- Anti-ST2 (MSTT1041A) in COPD (COPD-ST2OP)
- NCT number
- NCT03615040
- Phases
- PHASE2
- Conditions
- COPD Exacerbation
- Interventions
- MSTT1041A, Placebo
- Lead sponsor
- University of Leicester
- Results first posted
- 2022-05-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03615040?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03615040-76a5b24d